NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Merck & Co. Inc (NYSE: MRK)

 
MRK Technical Analysis
5
As on 24th Dec 2024 MRK STOCK Price closed @ 99.45 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 115.32 & Strong Sell for SHORT-TERM with Stoploss of 107.56 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

MRKSTOCK Price

Open 99.22 Change Price %
High 99.64 1 Day 0.08 0.08
Low 98.80 1 Week -2.55 -2.50
Close 99.45 1 Month -1.28 -1.27
Volume 3713295 1 Year -6.87 -6.46
52 Week High 132.96 | 52 Week Low 95.65
 
NYSE USA Most Active Stocks
FSR 0.02 0.00%
DDR 15.44 -4.46%
TWTR 53.70 0.66%
SWN 7.11 -0.56%
BACA-U 302.00 0.67%
RPAI 13.15 -3.17%
LTHM 16.51 -8.53%
SRC 42.31 -1.56%
AUY 5.85 -0.68%
PLTR 83.16 5.31%
 
NYSE USA Top Gainers Stocks
CND-WT 0.05 400.00%
MPLN 10.47 73.34%
MPLN 10.47 73.34%
MPLN 10.47 73.34%
WEI 0.44 51.72%
QFTA 10.26 51.33%
MOTV 18.70 50.20%
CORR 0.03 50.00%
KORE 1.92 43.28%
KORE 1.92 43.28%
 
NYSE USA Top Losers Stocks
AJX 0.01 -99.67%
AJX 0.01 -99.67%
AJX 0.01 -99.67%
QFTA-WS 0.46 -95.33%
TWND-WS 0.48 -95.12%
CHAA-WS 0.53 -94.56%
PMVC-WS 0.58 -94.10%
PIAI-WS 0.58 -94.09%
PCPC-WS 1.50 -93.83%
FTEV-WS 0.60 -93.81%
 
 
MRK
Daily Charts
MRK
Intraday Charts
Whats New @
Bazaartrend
MRK
Free Analysis
 
MRK Important Levels Intraday
RESISTANCE101.07
RESISTANCE100.55
RESISTANCE100.23
RESISTANCE99.91
SUPPORT98.99
SUPPORT98.67
SUPPORT98.35
SUPPORT97.83
 
MRK Forecast December 2024
4th UP Forecast116.25
3rd UP Forecast110.86
2nd UP Forecast107.53
1st UP Forecast104.2
1st DOWN Forecast94.7
2nd DOWN Forecast91.37
3rd DOWN Forecast88.04
4th DOWN Forecast82.65
 
MRK Weekly Forecast
4th UP Forecast109.61
3rd UP Forecast106.35
2nd UP Forecast104.34
1st UP Forecast102.32
1st DOWN Forecast96.58
2nd DOWN Forecast94.56
3rd DOWN Forecast92.55
4th DOWN Forecast89.29
 
MRK Forecast2024
4th UP Forecast176.82
3rd UP Forecast152.01
2nd UP Forecast136.67
1st UP Forecast121.33
1st DOWN Forecast77.57
2nd DOWN Forecast62.23
3rd DOWN Forecast46.89
4th DOWN Forecast22.08
 
 
MRK Other Details
Segment EQ
Market Capital 222532747264.00
Sector Healthcare
Industry Drug Manufacturers-General
Offical website >
 
MRK Address
MRK
 
MRK Latest News
 
Your Comments and Response on Merck & Co. Inc
 
MRK Business Profile
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment provides discovers, develops, manufactures, and markets a range of veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as a suite of digitally connected identification, traceability, and monitoring products. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; and Ridgeback Biotherapeutics. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaboration agreement with Hummingbird Bioscience Pte. Ltd; Gilead Sciences, Inc. to co-develop and co-commercialize long-acting investigational treatment combinations of Lenacapavir and Islatravir in HIV; Amathus Therapeutics to develop treatments for neurodegenerative diseases; Linnaeus Therapeutics, Inc. to evaluate LNS8801; Biomed X Gmbh for building on ongoing research projects in the fields of oncology and autoimmunity (intestinal epithelial barrier in autoimmune diseases); NGM Biopharmaceuticals, Inc. to focus primarily on the development of medicines in retinal and CVM diseases; and to develop and commercialize tests that identify genetic mutations, as well as with IO Biotech ApS to evaluate IO102-IO103. It also has a partnership with Biocorp Production for the development and supply of a specific version of Mallya device. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. Address: 2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service